Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection

NCT07028970 · tracked via the Priya Life Science China tracker

Sponsor

Nanjing IASO Biotechnology Co., Ltd.

Phase

Observational

Started

2024-12-15

Last updated

2025-06-19

Condition(s) studied

Multiple Myeloma

Investigational drug(s) / intervention(s)

No Intervention (subjects were previously treated with Equecabtagene Autoleucel Injection) )

No Intervention (subjects were previously treated with Equecabtagene Autoleucel Injection) ): This study is observational study and all participants will be obsreved with no intervention.

Study summary

This is a multicenter, open-label, single-arm, long-term follow-up clinical study. All patients who have received Equecabtagene Autoleucel Injection treatment will be enrolled.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: \- 1.Received Equecabtagene Autoleucel Injection treatment; 2.For those who participated in pre-marketing clinical studies or post-marketing real-world studies, must have completed or withdrawn from the original study; 3.Voluntary signing of an informed consent form approved by the ethics committee. Exclusion Criteria: * 1\. Receipt of another lentiviral vector-based cell or gene therapy (either commercialized product or investigational product in a clinical tiral) between the infution of Equecabtagene Autoleucel Injection and the signing informed consent.

Primary outcome measure(s)

To evaluate the safety profile of Equecabtagene Autoleucel Injection in treated patients. — Up to 15 years from enrollment

Trial sites (6)

Facility	City	Region	Status
Peking University First Hospital	Beijing	China	Not Yet Recruiting
People's Hospital of Peking Universit	Beijing	China	Not Yet Recruiting
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences	Tianjin	China	Recruiting
Tianjin Medical University General Hospital	Tianjin	China	Recruiting
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	Not Yet Recruiting
Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University	Zhengzhou	China	Not Yet Recruiting

More Nanjing IASO Biotechnology Co., Ltd. trials in China

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) Recruiting

UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies Recruiting

UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis Recruiting

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) Starting soon

A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy Starting soon

Other trials for the same condition

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not Recruiting

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL Recruiting

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma Recruiting

Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07028970 on ClinicalTrials.gov ↗ ← All trials in China